Ibex Wealth Advisors Raises Stock Holdings in Merck & Co., Inc. $MRK

Ibex Wealth Advisors boosted its position in shares of Merck & Co., Inc. (NYSE:MRK) by 6.6% in the first quarter, according to the company in its most recent filing with the SEC. The firm owned 101,148 shares of the company’s stock after acquiring an additional 6,268 shares during the quarter. Merck & Co., Inc. comprises about 1.1% of Ibex Wealth Advisors’ portfolio, making the stock its 25th largest position. Ibex Wealth Advisors’ holdings in Merck & Co., Inc. were worth $12,167,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in MRK. Chesapeake Wealth Management raised its stake in shares of Merck & Co., Inc. by 0.6% in the fourth quarter. Chesapeake Wealth Management now owns 14,740 shares of the company’s stock worth $1,552,000 after purchasing an additional 87 shares during the last quarter. South Plains Financial Inc. boosted its position in Merck & Co., Inc. by 0.6% in the fourth quarter. South Plains Financial Inc. now owns 15,535 shares of the company’s stock valued at $1,635,000 after buying an additional 89 shares during the last quarter. Syverson Strege & Co increased its holdings in Merck & Co., Inc. by 2.2% in the 4th quarter. Syverson Strege & Co now owns 4,142 shares of the company’s stock worth $436,000 after buying an additional 90 shares during the period. Nations Financial Group Inc. IA ADV increased its holdings in Merck & Co., Inc. by 0.4% in the 1st quarter. Nations Financial Group Inc. IA ADV now owns 23,433 shares of the company’s stock worth $2,819,000 after buying an additional 91 shares during the period. Finally, Westside Investment Management Inc. raised its position in Merck & Co., Inc. by 3.1% during the 4th quarter. Westside Investment Management Inc. now owns 3,142 shares of the company’s stock worth $331,000 after buying an additional 93 shares during the last quarter. Hedge funds and other institutional investors own 76.07% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have commented on MRK shares. Citigroup assumed coverage on shares of Merck & Co., Inc. in a research note on Wednesday, May 6th. They set a “neutral” rating and a $125.00 price objective for the company. CICC Research assumed coverage on shares of Merck & Co., Inc. in a research note on Wednesday, June 24th. They issued an “outperform” rating and a $138.00 price objective on the stock. JPMorgan Chase & Co. raised their target price on shares of Merck & Co., Inc. from $125.00 to $135.00 and gave the stock an “overweight” rating in a report on Monday, April 6th. UBS Group boosted their target price on shares of Merck & Co., Inc. from $130.00 to $145.00 and gave the company a “buy” rating in a research report on Monday, April 13th. Finally, Morgan Stanley upped their price target on shares of Merck & Co., Inc. from $112.00 to $113.00 and gave the company an “equal weight” rating in a report on Thursday. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and seven have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $132.72.

Merck & Co., Inc. Trading Down 0.7%

Shares of Merck & Co., Inc. stock opened at $125.17 on Friday. The firm has a 50-day simple moving average of $118.57 and a two-hundred day simple moving average of $116.23. The company has a debt-to-equity ratio of 1.02, a quick ratio of 1.06 and a current ratio of 1.30. Merck & Co., Inc. has a fifty-two week low of $76.66 and a fifty-two week high of $130.29. The company has a market cap of $309.14 billion, a P/E ratio of 35.26, a price-to-earnings-growth ratio of 2.69 and a beta of 0.19.

Merck & Co., Inc. (NYSE:MRK) last posted its earnings results on Thursday, April 30th. The company reported ($1.28) EPS for the quarter, beating analysts’ consensus estimates of ($1.47) by $0.19. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.The firm had revenue of $16.29 billion for the quarter, compared to analysts’ expectations of $15.85 billion. During the same period last year, the firm earned $2.22 EPS. The company’s quarterly revenue was up 4.9% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. As a group, equities analysts predict that Merck & Co., Inc. will post 5.19 earnings per share for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, July 8th. Stockholders of record on Monday, June 15th were given a $0.85 dividend. The ex-dividend date was Monday, June 15th. This represents a $3.40 dividend on an annualized basis and a dividend yield of 2.7%. Merck & Co., Inc.’s payout ratio is 95.77%.

Key Headlines Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck’s KEYTRUDA franchise got a boost from recent U.S. and EU approvals in breast and bladder cancer, expanding its use in hard-to-treat tumors and strengthening the company’s oncology growth story. Article Title
• Positive Sentiment: Merck also reached a new access agreement for its HIV treatment, IDVYNSO, which could modestly improve market access and commercial momentum for the product. Article Title
• Positive Sentiment: Several analysts remain constructive on Merck, including recent price-target increases from RBC and Wells Fargo, reflecting confidence in the company’s pipeline and KEYTRUDA-driven earnings power. Article Title
• Neutral Sentiment: Merck has been attracting elevated investor attention, but the related coverage is more about monitoring the stock’s setup than a new business catalyst. Article Title
• Neutral Sentiment: A market report on Southeast Asia oncology drug access listed Merck among peer companies, highlighting the broader opportunity for cancer therapy access but not pointing to a company-specific development. Article Title
• Negative Sentiment: Morgan Stanley trimmed its price target to $113 and kept an equal-weight rating, signaling limited near-term upside from current levels and reinforcing valuation caution. Article Title

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.